Compare Amphastar Pharmaceuticals Inc (AMPH) vs AXT Inc (AXTI) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

AXTI trades at $57.21, down 8.54% today amid bearish technical signals. The company shows negative profitability with a -14.68% net margin but has beaten EPS estimates in two of the last three quarters. Analyst consensus is bullish with 64% buy ratings, supported by a $100M backlog and AI-driven indium phosphide demand growth. Cash flow remains positive primarily from financing activities.

Near-term outlook hinges on Q2 2026 earnings due July 30, where analysts expect EPS of $0.07. Key opportunities include AI infrastructure expansion and capacity growth, while risks involve geopolitical tensions affecting Chinese exports and ongoing negative cash flow from operations. The stock faces resistance near $66 with support at $55.